How large is the sickle cell anemia testing and screening market?

In 2027 the market for sickle cell anemia testing and screening is worth approximately USD 566.95 million.

What is the expected industry size of sickle cell anemia testing and screening by 2036?

Sickle Cell Anemia Testing and Screening Market size was more than USD 516.91 million in 2026 and is set to grow at a 11.5% CAGR between 2027 and 2036, attaining USD 1.54 billion by 2036.

How are government-led newborn screening programs influencing growth in the sickle cell anemia testing and screening market?

Government-backed screening initiatives are creating sustained testing demand through mandatory programs, centralized procurement, reimbursement support, and expanded public health networks, increasing adoption across hospitals, laboratories, and community healthcare systems.

Why are molecular diagnostics becoming increasingly important in the sickle cell anemia testing and screening market?

Advances in PCR and genetic testing enable faster, more accurate diagnosis and carrier identification, encouraging healthcare providers to integrate molecular methods into standardized protocols for newborn, prenatal, and family-based screening.

Why does newborn screening lead the sickle cell anemia testing and screening market?

Newborn Screening accounted for a 44.63% share in 2026 because it is embedded in standardized neonatal and pediatric care pathways, making early-life testing a consistent and routine source of screening demand.

Why are private labs the fastest-growing sector in the sickle cell anemia testing and screening market?

Private Labs are growing rapidly as healthcare providers and patients seek faster processing, greater accessibility, and more flexible testing services beyond traditional public laboratory networks.

Why does North America lead the sickle cell anemia testing and screening market?

North America holds 46.64% share due to established newborn screening programs, strong diagnostic lab access, and structured care pathways linking screening with confirmatory testing and disease management.

What is driving Europe’s fastest growth in sickle cell anemia testing and screening market?

Europe’s 13.44% CAGR is driven by expanding screening protocols, integration into public health systems, and stronger referral pathways enabling earlier detection and higher diagnostic testing volumes.

Who holds a significant market share in the sickle cell anemia testing and screening landscape?

Prominent companies in the sickle cell anemia testing and screening market include Roche Diagnostics (Switzerland), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (USA), Bio-Rad Laboratories, Inc. (USA), Laboratory Corporation of America Holdings (USA), Quest Diagnostics Incorporated (USA), Streck, Inc. (USA), Daktari Diagnostics (USA), Hemex Health, Inc. (USA), BIOMEDOMICS INC (USA).